{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:00Z","timestamp":1794047460749,"version":"4.8.0"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Venetoclax with azacitidine (ven\/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients with acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry is a valuable tool for the prediction of relapse in AML using conventional therapies and ven\/aza; however, the prognostic value for broadscale molecular MRD after ven\/aza treatment is less clear. We aimed to determine the utility of retrospective assessment using multi-gene molecular MRD by droplet digital polymerase chain reaction (ddPCR). We found this approach correlates with outcomes in a cohort of patients receiving frontline ven\/aza for AML. The predictive value of ddPCR MRD persisted when NPM1 mutations were removed from analysis, as well as after adjustment for the impact of stem cell transplant on outcomes. Late achievement of MRD negativity, including after SCT, was still associated with superior outcomes compared to persistently detectable MRD. We further explored the impact of ven\/aza on the burden of different classes of mutations, and identified the persistence of splicing factor mutations, commonly associated with MDS, as a consistent finding after ven\/aza treatment. These data add to our understanding of the effects of ven\/aza on AML disease biology and provide details on molecular depth of remission that can guide prospective trials in the future.<\/jats:p>","DOI":"10.3324\/haematol.2023.283790","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T03:19:45Z","timestamp":1702523985000},"page":"1766-1778","source":"Crossref","is-referenced-by-count":11,"title":["Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax\/azacitidine"],"prefix":"10.3324","volume":"109","author":[{"given":"Amanda C.","family":"Winters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Minhajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Bosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Miltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Treece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford J.","family":"Siegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Ewalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"61833","doi-asserted-by":"crossref","unstructured":"Short NJ, Zhou S, Fu C. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020; 6(12):1890-1899.","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"61834","doi-asserted-by":"crossref","unstructured":"Buckley SA, Wood BL, Othus M. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017; 102(5):865-873.","DOI":"10.3324\/haematol.2016.159343"},{"key":"61835","doi-asserted-by":"crossref","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767.","DOI":"10.1182\/blood.2021013626"},{"key":"61836","doi-asserted-by":"crossref","unstructured":"Klco JM, Miller CA, Griffith M. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015; 314(8):811-822.","DOI":"10.1001\/jama.2015.9643"},{"key":"61837","doi-asserted-by":"crossref","unstructured":"Ivey A, Hills RK, Simpson MA. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016; 374(5):422-433.","DOI":"10.1056\/NEJMoa1507471"},{"key":"61838","doi-asserted-by":"crossref","unstructured":"Dillon LW, Higgins J, Nasif H. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. medRxiv. 2023.","DOI":"10.1101\/2023.03.26.23287367"},{"key":"61839","doi-asserted-by":"crossref","unstructured":"Hasserjian RP, Steensma DP, Graubert TA, Ebert BL. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood. 2020; 135(20):1729-1738.","DOI":"10.1182\/blood.2019004770"},{"key":"61840","doi-asserted-by":"crossref","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018; 378(13):1189-1199.","DOI":"10.1056\/NEJMoa1716863"},{"key":"61841","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23):2209-2221.","DOI":"10.1056\/NEJMoa1516192"},{"key":"61842","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-2074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"61843","doi-asserted-by":"crossref","unstructured":"Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018; 19(5):269-285.","DOI":"10.1038\/nrg.2017.117"},{"key":"61844","doi-asserted-by":"crossref","unstructured":"Maier J, Lange T, Cross M, Wildenberger K, Niederwieser D, Franke GN. Optimized digital droplet PCR for BCR-ABL. J Mol Diagn. 2019; 21(1):27-37.","DOI":"10.1016\/j.jmoldx.2018.08.012"},{"key":"61845","doi-asserted-by":"crossref","unstructured":"Bacher U, Dicker F, Haferlach C. Quantification of rare NPM1 mutation subtypes by digital PCR. Br J Haematol. 2014; 167(5):710-714.","DOI":"10.1111\/bjh.13038"},{"key":"61846","doi-asserted-by":"crossref","unstructured":"Brambati C, Galbiati S, Xue E. Droplet digital polymerase chain reaction for DNMT3A and IDH1\/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016; 101(4):e157-161.","DOI":"10.3324\/haematol.2015.135467"},{"key":"61847","doi-asserted-by":"crossref","unstructured":"Wei AH, Strickland SA, Hou JZ. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019; 37(15):1277-1284.","DOI":"10.1200\/JCO.18.01600"},{"key":"61848","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Pratz K, Letai A. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021; 96(2):208-217.","DOI":"10.1002\/ajh.26039"},{"key":"61849","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"61850","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Tiong IS, Quaglieri A. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803.","DOI":"10.1182\/blood.2019003988"},{"key":"61851","doi-asserted-by":"crossref","unstructured":"Pei S, Pollyea DA, Gustafson A. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020; 10(4):536-551.","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"61852","doi-asserted-by":"crossref","unstructured":"Stevens BM, Jones CL, Pollyea DA. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020; 1(12):1176-1187.","DOI":"10.1038\/s43018-020-00126-z"},{"key":"61853","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Winters A, McMahon C. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022; 57(2):160-166.","DOI":"10.1038\/s41409-021-01476-7"},{"key":"61854","doi-asserted-by":"crossref","unstructured":"Chua CC, Hammond D, Kent A. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022; 6(13):3879-3883.","DOI":"10.1182\/bloodadvances.2022007083"},{"key":"61855","doi-asserted-by":"crossref","unstructured":"Pratz KW, Jonas BA, Pullarkat V. Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022; 40(8):855-865.","DOI":"10.1200\/JCO.21.01546"},{"key":"61856","doi-asserted-by":"crossref","unstructured":"Maiti A, DiNardo CD, Wang SA. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021; 5(7):1876-1883.","DOI":"10.1182\/bloodadvances.2020003717"},{"key":"61857","doi-asserted-by":"crossref","unstructured":"Bazinet A, Kadia TM, Short NJ. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023; 7(13):3284-3296.","DOI":"10.1182\/bloodadvances.2022009391"},{"key":"61858","doi-asserted-by":"crossref","unstructured":"Ong SY, Tan Si Yun M, Abdul Halim NA. Real-world experience of measurable residual disease response and prognosis in acute myeloid leukemia treated with venetoclax and azacitidine. Cancers (Basel). 2022; 14(15):3576.","DOI":"10.3390\/cancers14153576"},{"key":"61859","doi-asserted-by":"crossref","unstructured":"Tiong IS, Dillon R, Ivey A. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2021; 192(6):1026-1030.","DOI":"10.1111\/bjh.16722"},{"key":"61860","doi-asserted-by":"crossref","unstructured":"Othman J, Tiong IS, O\u2019Nions J. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy. Blood. 2024; 143(4):336-341.","DOI":"10.1182\/blood.2023021579"},{"key":"61861","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Stevens BM, Jones CL. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24(12):1859-1866.","DOI":"10.1038\/s41591-018-0233-1"},{"key":"61862","doi-asserted-by":"crossref","unstructured":"Winters AC, Gutman JA, Purev E. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019; 3(20):2911-2919.","DOI":"10.1182\/bloodadvances.2019000243"},{"key":"61863","doi-asserted-by":"crossref","unstructured":"Gutman JA, Winters A, Kent A. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023; 108(10):2616-2625.","DOI":"10.3324\/haematol.2023.282681"},{"key":"61864","doi-asserted-by":"crossref","unstructured":"Valent P, Orazi A, Steensma DP. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017; 8(43):73483-73500.","DOI":"10.18632\/oncotarget.19008"},{"key":"61865","doi-asserted-by":"crossref","unstructured":"Lindsley RC, Mar BG, Mazzola E. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-1376.","DOI":"10.1182\/blood-2014-11-610543"},{"key":"61866","doi-asserted-by":"crossref","unstructured":"McCarter JGW, Nemirovsky D, Famulare CA. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv. 2023; 7(17):5000-5013.","DOI":"10.1182\/bloodadvances.2023009675"},{"key":"61867","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"61868","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"61869","doi-asserted-by":"crossref","unstructured":"Uy GL, Duncavage EJ, Chang GS. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2017; 31(4):872-881.","DOI":"10.1038\/leu.2016.282"},{"key":"61870","doi-asserted-by":"crossref","unstructured":"Mencia-Trinchant N, Hu Y, Alas MA. Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn. 2017; 19(4):537-548.","DOI":"10.1016\/j.jmoldx.2017.03.005"},{"key":"61871","doi-asserted-by":"crossref","unstructured":"Grassi S, Guerrini F, Ciabatti E. Digital droplet PCR is a specific and sensitive tool for detecting IDH2 mutations in acute myeloid leuKemia patients. Cancers (Basel). 2020; 12(7):1738.","DOI":"10.3390\/cancers12071738"},{"key":"61872","doi-asserted-by":"crossref","unstructured":"Rausch C, Rothenberg-Thurley M, Buerger SA. Double prop-off droplet digital PCR: a novel, versatile tool for mutation screening and residual disease monitoring in acute myeloid leukemia using cellular or cell-free DNA. J Mol Diagn. 2021; 23(8):975-985.","DOI":"10.1016\/j.jmoldx.2021.05.001"},{"key":"61873","doi-asserted-by":"crossref","unstructured":"Hourigan CS, Dillon LW, Gui G. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020; 38(12):1273-1283.","DOI":"10.1200\/JCO.19.03011"},{"key":"61874","doi-asserted-by":"crossref","unstructured":"Bae JH, Liu R, Roberts E. Single duplex DNA sequencing with CODEC detects mutations with high sensitivity. Nat Genet. 2023; 55(5):871-879.","DOI":"10.1038\/s41588-023-01376-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283790\/76392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283790\/77057","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11377\/76392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:26Z","timestamp":1794045926000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283790","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}